Clinical trial
A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy…
NCT00414050 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00414050 |
|---|---|
| Title | A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) |
| Official title | A Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Modified Process Hepatitis B Vaccine (Experimental), Hepatitis B Vaccine (Recombinant) |
| Enrollment | 1,718 |
| Start date | Oct 6, 2006 |
| Primary completion | Oct 22, 2007 |
| Completion | Oct 24, 2007 |
| First posted | Dec 21, 2006 |
| Last update posted | May 23, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: